Ciltacabtagene autoleucel适用于既往接受过多线治疗(包括蛋白酶体抑制剂、免疫调节剂和抗CD38单克隆抗体)的复发或难治性多发性骨髓瘤患者。 在给予Ciltacabtagene autoleucel治疗前,患者需要接受淋巴细胞去除化疗,以降低肿瘤负荷和增强CAR-T细胞的扩增和持续性。 Ciltacabtagene autoleucel为一次性输注治疗,剂量根据...
FDA批准BCMA CAR-T疗法Cilta-cel(Ciltacabtagene autoleucel、西达基奥仑塞、Carvykti)上市,价格适应症都公布了 今天早上,我们迎来一个重磅好消息!FDA批准传奇生物的靶向BCMA CAR-T疗法--Carvykti 上市,用于治疗复发或难治性多发性骨髓瘤(R/R MM)患者,这些患者既往接受过四种或四种以上的治疗,包括蛋白酶体抑制...
FDA Approval for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma. Available at: https://legendbiotech.com/legend-news/carvykti-ciltacabtagene-autoleucel-bcma-directed- car-t-therapy-receives-u-s-fda-approval-for-the-treatment-of-adult-patients-with-relapsed-or-...
In earlier lines of therapy, patients with relapsed/refractory multiple myeloma (MM) receiving the anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy, ciltacabtagene autoleucel (Carvykti; cilta-cel), showed deep, durable responses leading to 95% and...
About CARVYKTI®(ciltacabtagene autoleucel; cilta-cel) CARVYKTI®received U.S. Food and Drug Administrationapprovalin February 2022 for the treatment of adults with relapsed or refractory multiple myeloma af...
8JnJ.com U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myel...
G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet 398, 314–324 (2021). Article CAS PubMed Google Scholar Ri,...